Antisoma vergibt Auftrag an BioInvent (heute früh gemeldet) - 500 Beiträge pro Seite

[Aktientiger]

Antisoma and BioInvent sign BC-1 monoclonal antibody manufacturing
agreement


London, UK & Lund, Sweden: 11 April 2001 Antisoma plc (LSE:ASM,
EASD:ASOM) and BioInvent International AB today announce an agreement for the production of muBC-1, a murine monoclonal antibody. muBC-1 will be used by Antisoma to develop a radiolabelled product, AngioMab, which is a
potential anti-angiogenic treatment for targeted cancer therapy.

Under the agreement, BioInvent, through its subsidiary BioInvent Production AB, will carry out process development and GMP (Good Manufacturing Practice) production of the antibody ready for radiolabelling, to meet both European (EMEA) and US (FDA) standards for clinical studies.

It is currently expected that AngioMab will start Phase I human clinical studies at the end of 2001. The product will be initially developed for intracranial delivery to treat glioblastoma multiforme, an aggressive form of brain cancer. These tumours are often unresponsive to chemotherapy and are usually treated by surgery and radiotherapy. There is a significant need to improve the low response and poor survival rates following standard therapy.

Commenting on the agreement, Glyn Edwards, Chief Executive of Antisoma,
said:

"We have worked with BioInvent for more than four years and are pleased to extend the collaboration to a second product. BioInvent have manufactured clinical supplies for our Phase III ovarian cancer study with pemtumomab. With the ever increasing number of biologicals entering clinical trials, the development of a sound relationship with BioInvent and the securing of manufacturing capacity is paramount to our bringing new molecules forward for clinical trials. Antisoma aims to have at least one more product in clinical development by the end of this year, and
securing this agreement for AngioMab takes us a step closer to our goal.
" Cristina Glad, President of BioInvent Production AB, added:
"Antisoma`s decision to place the order for process development and GMP manufacturing of their second antibody with BioInvent demonstrates their continued confidence in our expertise. We look forward to extending the excellent collaboration we already have with Antisoma."

- ENDS -

[GRILLER]

deswegen gings heute auch teilweise bis zu 12% hoch.

ist ja sehr erfreulich!

bis denn griller

[Aktientiger]

Hallöchen an alle Antisoma - Fans

mit der neusten Veröffentlichung von Antisoma am 30.04. hat sich bei mir die Meinung verfestigt, dass Antisoma offensichtlich in der Lage ist wirklich vielverprechende Wirkstoffe zu entwickeln. Von dieser Seite her gesehen, könnte Antisoma eine wirklich vielverprechende Investition werden. Hauptsache, die finanzielle Situation ist weiterhin gesichert, so sollte Antisoma m.E. nach weiteren starken Partnern suchen, die z.B. Therex vermarkten und Antisoma mit Meilensteinzahlungen über Wasser halten.
Die Finanzen bleiben der wunde Punkt. Das sie was können, wird mit jedem Tag deutlicher.

Was meint Ihr zum Thema Finanzen bei Antisoma?

Einen schönen Tag noch.